New trial
Phase 1 Study: Dose Escalation of DZD6008 in EGFR-Mutant Advanced NSCLC
- Trial ID
- NCT06905197 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer
- Published in
- New in Oncology - May 14, 2025
Dizal Pharmaceuticals is assessing DZD6008, an EGFR (brain-blood barrier positive) inhibitor, across multiple dose escalation cohorts to evaluate its safety, tolerability, pharmacokinetics, and antitumor efficacy in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations.
More on NCT06905197
-
Trial result · Jun 11, 2026
DZD6008 (4th-gen EGFR TKI) posts 60% ORR at 60mg in EGFR C797X+ post–osimertinib NSCLC
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC